Compare CBNK & BLSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CBNK | BLSM |
|---|---|---|
| Founded | 1974 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 483.4M |
| IPO Year | 2018 | 2026 |
| Metric | CBNK | BLSM |
|---|---|---|
| Price | $42.10 | $13.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $44.08 | $35.40 |
| AVG Volume (30 Days) | 136.9K | ★ 140.5K |
| Earning Date | 10-26-2026 | 11-23-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ 60.85 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.98 | N/A |
| Revenue Next Year | $10.68 | N/A |
| P/E Ratio | $17.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.40 | $11.02 |
| 52 Week High | $44.76 | $27.99 |
| Indicator | CBNK | BLSM |
|---|---|---|
| Relative Strength Index (RSI) | 58.96 | 42.60 |
| Support Level | $35.70 | $12.93 |
| Resistance Level | N/A | $17.53 |
| Average True Range (ATR) | 0.94 | 1.77 |
| MACD | -0.05 | 0.10 |
| Stochastic Oscillator | 40.77 | 41.17 |
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage. The company generates majority revenue from the Commercial bank sector. Commercial Banking division focuses on providing personalized service to commercial clients throughout the operations supplemented by lending outside primary market as well as engaging in government guaranteed lending on a national basis.
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.